Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 18

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 18
---
 |

| (2) | The                                                                                                                                 
 number of shares of our Common Stock that will be outstanding after this Offering is based on 60,729,100 shares of our Common Stock 
 outstanding as of October 3, 2025 and excludes:                                                                                     |

| ● | 4,270,000                                                                                                                        
 shares of Common stock issuable upon the exercise of outstanding stock options as of September 30, 2025, granted pursuant to our 
 Global Share Incentive Plan (2021), as amended (the “2021 Plan”), at a weighted-average exercise price of $0.0.30 per            
 share and                                                                                                                        |

| ● | 2,930,000                                                                                                                     
 shares of Common Stock reserved, in the aggregate, for future issuance under our 2021 Plan, as amended, as of October 3, 2025 |

| ● | 6,372,265 Common Stock                                                                                                                
 issuable upon the exercise of our outstanding warrants with the average exercise price of $1.16 per share, exercisable until December 
 31, 2026.                                                                                                                             |

Except as otherwise indicated, all information in this Prospectus:

<div align='center'>4

RISK FACTOR SUMMARY</div>

The following is
a summary of the principal risks that could adversely affect our business, operations, and financial results. A more thorough discussion
of these and other risks are listed under the section entitled “Risk Factors” commencing on page 5.

Risks Relating to the Company’s Business and Financial Position

| ● | We have a History of                                                                                                                     
 Losses and May Never Achieve Profitability.                                                                                              |
| ● | We will need substantial                                                                                                                 
 additional funding to realize our business plan. We may not be able to raise capital when needed, if at all, which would force us        
 to delay, reduce or eliminate our product development programs or commercialization efforts and could cause our business to fail.        |
| ● | We anticipate that we                                                                                                                    
 can successfully develop the acquired business of LipoVation resulting from the closing of the Share Exchange. However, if we fail       
 to comply with LipoVation’s contractual obligations under the Yissum License Agreements or other licenses or related agreements          
 to which we may be a party in the future, we could lose license rights that may be necessary for developing our Nano-Liposomal Particles 
 (NLP)-based medicines based therapeutic products.                                                                                        |
| ● | Our Chief